VEGFA and non-small cell lung carcinoma: It should be emphasized, however, that our study is based on the analysis of a significantly larger cohort of patients (N = 500), as well as a broader spectrum of the analyzed pro-angiogenic factors (CD31, CD34, CD105, and VEGF-A), as opposed to the relatively small number of patients with NSCLC (N = 88) and the single marker (von Willebrand factor antigen; F8RA) assessed in the study conducted by Takanami et al. [55].